2024
IOVA Iovance Biotherapeutics Inc
PUYI Puyi Inc
IFBD Infobird Co Ltd
FREE Whole Earth Brands Inc
Go

Health Care : Pharmaceuticals | Small Cap Value

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Closing Price: $2.63

Day's Change: -0.07 (-2.59%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.70

Day's Low: 2.56

Volume (Heavy Day) Volume: 221,046 10-day average volume: 155,399: 221,046

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.